Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Septerna, Inc. ( (SEPN) ) just unveiled an announcement.
On July 1, 2025, Septerna, Inc. announced the effectiveness of its Collaboration and License Agreement with Novo Nordisk A/S, following the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. This agreement, initially announced on May 13, 2025, marks a significant step in Septerna’s strategic partnerships, potentially enhancing its market position and operational capabilities.
The most recent analyst rating on (SEPN) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Septerna, Inc. stock, see the SEPN Stock Forecast page.
Spark’s Take on SEPN Stock
According to Spark, TipRanks’ AI Analyst, SEPN is a Neutral.
Septerna, Inc. faces a challenging financial situation with significant operational inefficiencies and cash flow issues. While the collaboration with Novo Nordisk provides a strategic advantage, the lack of valuation metrics and mixed technical indicators contribute to an uncertain outlook. The company’s strong equity base and low leverage are positive, but improvements in operational efficiency are crucial for future stability.
To see Spark’s full report on SEPN stock, click here.
More about Septerna, Inc.
Average Trading Volume: 1,097,012
Technical Sentiment Signal: Hold
Current Market Cap: $472.3M
For detailed information about SEPN stock, go to TipRanks’ Stock Analysis page.